GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » Operating Income

WuXi Biologics (Cayman) (HKSE:02269) Operating Income : HK$4,392 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Operating Income?

WuXi Biologics (Cayman)'s Operating Income for the six months ended in Jun. 2024 was HK$2,322 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$4,392 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. WuXi Biologics (Cayman)'s Operating Income for the six months ended in Jun. 2024 was HK$2,322 Mil. WuXi Biologics (Cayman)'s Revenue for the six months ended in Jun. 2024 was HK$9,231 Mil. Therefore, WuXi Biologics (Cayman)'s Operating Margin % for the quarter that ended in Jun. 2024 was 25.15%.

Good Sign:

WuXi Biologics (Cayman) Inc operating margin is expanding. Margin expansion is usually a good sign.

WuXi Biologics (Cayman)'s 5-Year average Growth Rate for Operating Margin % was 1.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. WuXi Biologics (Cayman)'s annualized ROC % for the quarter that ended in Jun. 2024 was 8.79%. WuXi Biologics (Cayman)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 12.26%.


WuXi Biologics (Cayman) Operating Income Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Operating Income Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,176.24 2,088.18 4,242.37 5,358.39 4,867.53

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,120.03 2,386.05 2,797.11 2,070.43 2,321.57

WuXi Biologics (Cayman) Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4,392 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (HKSE:02269) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

WuXi Biologics (Cayman)'s annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=4643.148 * ( 1 - 11.36% )/( (45892.372 + 47733.94)/ 2 )
=4115.6863872/46813.156
=8.79 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=61881.335 - 3691.129 - ( 12297.834 - max(0, 8352.117 - 23186.197+12297.834))
=45892.372

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=60400.246 - 2408.264 - ( 10258.042 - max(0, 7329.371 - 21333.583+10258.042))
=47733.94

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

WuXi Biologics (Cayman)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=4470.78/( ( (32747.161 + max(2686.033, 0)) + (33131.41 + max(4389.857, 0)) )/ 2 )
=4470.78/( ( 35433.194 + 37521.267 )/ 2 )
=4470.78/36477.2305
=12.26 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6183.821 + 1931.341 + 2123.099) - (3691.129 + 0 + 3861.099)
=2686.033

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6166.687 + 2112.764 + 2271.518) - (2408.264 + 0 + 3752.848)
=4389.857

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

WuXi Biologics (Cayman)'s Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=2321.574/9230.514
=25.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


WuXi Biologics (Cayman) Operating Income Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) Business Description

Traded in Other Exchanges
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Executives
Blackrock, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Li Ge 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Brown Brothers Harriman & Co. 2502 Approved lending agent
Zhao Ning 2202 Interest of your spouse
Liu Xiaozhong 2401 A concert party to an agreement to buy shares
New Wuxi Life Science Holdings Limited 2201 Interest of corporation controlled by you
New Wuxi Life Science Limited 2201 Interest of corporation controlled by you
Wuxi Biologics Holdings Limited 2101 Beneficial owner
Wuxi Pharmatech (cayman) Inc. 2201 Interest of corporation controlled by you
Zhang Zhaohui 2401 A concert party to an agreement to buy shares
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you

WuXi Biologics (Cayman) Headlines

No Headlines